TCM
MNPR icon

TCG Crossover Management’s Monopar Therapeutics MNPR Stock Holding History

TCG Crossover Management’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.8M Buy
203,327
+71,224
+54% +$4.41M 0.45% 42
2026
Q1 		$7.24M Sell
132,103
-9,812
-7% -$593K 0.21% 42
2025
Q4 		$9.27M Sell
141,915
-11,085
-7% -$906K 0.31% 36
2025
Q3 		$12.5M Buy
+153,000
New +$6.84M 0.61% 31

Other funds holding MNPR

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TCG Crossover Management's MNPR Position: Q2 2026 in Review

TCG Crossover Management increased its Monopar Therapeutics (MNPR) stake by 54% in Q2 2026, buying an estimated $4.41M and bringing the position to 203,327 shares worth $18.8M. The position accounts for 0.45% of the portfolio, ranked #42.

TCG Crossover Management first reported a position in MNPR in Q3 2025 and has held it in 4 quarters since. 96 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • TCG Crossover Management held 203,327 shares of Monopar Therapeutics worth $18.8M as of Q2 2026.
  • TCG Crossover Management bought 71,224 Monopar Therapeutics shares in Q2 2026, an estimated $4.41M.
  • Monopar Therapeutics made up 0.45% of TCG Crossover Management's portfolio in Q2 2026, its #42 holding.
  • TCG Crossover Management first reported a position in Monopar Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 96 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on TCG Crossover Management's 13F filing for Q2 2026, filed 14 Aug 2026.